Great Point Partners’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Great Point Partners’s Portfolio ECYT Stock Details ECYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1,606,100	Closed	-$28.5M	–	45
2018 Q3	$28.5M	Buy	+1,606,100	New	+$27.6M	4.45%	9
2018 Q2	–	Sell	-1,491,500	Closed	-$13.6M	–	51
2018 Q1	$13.6M	Buy	+1,491,500	New	+$8.23M	2.01%	20

Other funds holding ECYT

OTC

Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return

Claro Advisors Boston, Massachusetts $953M AUM 24.79% 1-Year Est. Return

Great Point Partners's ECYT Position: Q4 2018 in Review

Great Point Partners sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2018, closing a stake of 1,606,100 shares — an estimated $28.5M sold.

Great Point Partners first reported a position in ECYT in Q1 2018 and held it in 2 quarters. The position peaked at $28.5M in Q3 2018. 2 funds tracked by Wall St. Rank hold ECYT as of Q4 2018.

Great Point Partners reported no remaining Endocyte, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
Great Point Partners sold 1,606,100 Endocyte, Inc. Common Stock shares in Q4 2018, an estimated $28.5M.
Great Point Partners first reported a position in Endocyte, Inc. Common Stock in Q1 2018 and held it in 2 quarters.
Great Point Partners's Endocyte, Inc. Common Stock position peaked at $28.5M in Q3 2018.
2 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2018.

Based on Great Point Partners's 13F filing for Q4 2018, filed 15 Feb 2019.